Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11097275 | 0.74 | WDR5 (0.46) | KDM4EALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL11193638 | 0.72 | ALDH1A1 (0.41) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL2608598 | 0.68 | UHRF1 (0.37) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL9570028 | 0.68 | KDM4E (0.35) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL19514974 | 0.68 | KDM4E (0.35) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL9597366 | 0.68 | KDM4E (0.32) | KDM4EALDH1A1POLB | |
| SCHEMBL4766087 | 0.67 | ALDH1A1 (0.47) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL7008953 | 0.66 | ALDH1A1 (0.42) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL16387194 | 0.65 | KDM4E (0.32) | KDM4EALDH1A1POLBRAB9A | |
| SCHEMBL9869341 | 0.64 | POLB (0.38) | KDM4EALDH1A1POLBSPRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309565-B1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-6878704-B2 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1309565-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012199-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | MLN, MSH2, MRPL21 | KDM4E 4142/4885ALDH1A1 852/4885POLB 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.